We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA to Require More Robust Safety Data for Chronic Pain Drugs
FDA to Require More Robust Safety Data for Chronic Pain Drugs
Sponsors of new drugs and biologics for chronic pain may have to submit more safety data than they would to support acute pain candidates, an FDA draft guidance says.